Key result
New quinazoline-modified nucleoside analogues inhibit SARS-CoV-2 RdRp in vitro but underperform commercial analogues.
Why the study?
There have not been any effective FDA-approved drugs to treat COVID-19 despite available vaccines, motivating the search for new nucleoside analogues targeting SARS-CoV-2 polymerase.
Five newly synthesized nucleoside analogues were evaluated in vitro for their ability to inhibit SARS-CoV-2 polymerase.
Answers are grounded in this paper and cite their sources.
These quinazoline analogues show preliminary in vitro RdRp inhibition; leaves open whether modifications can match commercial potency in vivo.
Despite the fact that COVID-19 vaccines are already available on the market, there have not been any effective FDA-approved drugs to treat this disease. There are several already known drugs that through drug repositioning have shown an inhibitory activity against SARS-CoV-2 RNA-dependent RNA polymerase. These drugs are included in the family of nucleoside analogues. In our efforts, we synthesized a group of new nucleoside analogues, which are modified at the sugar moiety that is replaced by a quinazoline entity. Different nucleobase derivatives are used in order to increase the inhibition. Five new nucleoside analogues were evaluated with in vitro assays for targeting polymerase of SARS-CoV-2.
No takes yet. Share an insight, caveat, or question.
Daikopoulou et al. (2021) studied SARS-CoV-2 infection. Quinazoline-modified nucleoside analogues vs. Commercial inhibitors (Cordycepin 5'-triphosphate sodium salt) and non-modified analogues was evaluated on Inhibition of SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) in vitro. Newly synthesized quinazoline-modified nucleoside analogues demonstrated in vitro inhibition of SARS-CoV-2 RNA-dependent RNA polymerase, though the inhibition was not as strong as commercial analogues.
Synapse has enriched 10 related papers. Consider them for comparative context: